These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12778887)

  • 21. Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
    Lioulios G; Stangou M; Sarafidis PA; Tsouchnikas I; Minasidis I; Vainas A; Faitatzidou D; Sampani E; Papagianni A
    Blood Purif; 2020; 49(4):440-447. PubMed ID: 32050202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 25. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 27. [Efficiency of implementing a program aimed at achieving early referral to the nephrologist of patients with chronic renal failure in primary care].
    Aguilar MD; Orte L; Lázaro P; Gómez-Campderá FJ; Fernández Giráldez E; Sanz Guajardo D; Pastor V;
    Nefrologia; 2006; 26 Suppl 3():114-20. PubMed ID: 17469437
    [No Abstract]   [Full Text] [Related]  

  • 28. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.
    Panesar A; Agarwal R
    Am J Kidney Dis; 2002 Nov; 40(5):924-31. PubMed ID: 12407636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
    Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
    Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 33. A star rises, another fades.
    Neumann ME
    Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
    [No Abstract]   [Full Text] [Related]  

  • 34. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved response to erythropoietin therapy with long-term continuous iron supplementation.
    Descombes E; Fellay G
    Nephron; 2000 Feb; 84(2):196-7. PubMed ID: 10657727
    [No Abstract]   [Full Text] [Related]  

  • 36. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
    Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
    BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dialysis facility profit status and compliance with a black box warning.
    Ishida JH; McCulloch CE; Dudley RA; Grimes BA; Johansen KL
    JAMA Intern Med; 2013 Jun; 173(12):1152-3. PubMed ID: 23699967
    [No Abstract]   [Full Text] [Related]  

  • 40. Iron indices after administration of sodium ferric gluconate complex in hemodialysis patients.
    Shalansky K; Hanko J; Pudek M; Li G; Jastrzebski J
    Am J Kidney Dis; 2011 Oct; 58(4):684-5. PubMed ID: 21840100
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.